XML 34 R23.htm IDEA: XBRL DOCUMENT
v3.22.2.2

SEGMENT INFORMATION | 9 Months Ended
--- | ---
Sep. 30, 2022
Segment Reporting [Abstract] |
SEGMENT INFORMATION | SEGMENT INFORMATION We are organized into three reporting segments. Operations that sell dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer health care, injectables, active material science solutions and digital health markets form the Pharma segment. Operations that sell dispensing systems and sealing solutions primarily to the beauty, personal care and home care markets form the Beauty + Home segment. Operations that sell dispensing systems, sealing solutions and food service trays to the food and beverage markets form the Food + Beverage segment. The accounting policies of the segments are the same as those described in Part II, Item 8, Note 1 - Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2021. We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Financial information regarding our reporting segments is shown below:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Total Sales: |  |  |  |  |  |  |
Pharma | $ | 345,079 |  |  | $ | 317,358 |  |  | $ | 1,037,120 |  |  | $ | 961,718 |
Beauty + Home | 365,105 |  |  | 378,158 |  |  | 1,117,070 |  |  | 1,098,176 |
Food + Beverage | 133,869 |  |  | 138,735 |  |  | 401,758 |  |  | 381,356 |
Total Sales | $ | 844,053 |  |  | $ | 834,251 |  |  | $ | 2,555,948 |  |  | $ | 2,441,250 |
Less: Intersegment Sales: |  |  |  |  |  |  |
Pharma | $ | 1,682 |  |  | $ | 4,133 |  |  | $ | 11,030 |  |  | $ | 9,318 |
Beauty + Home | 5,282 |  |  | 4,070 |  |  | 17,702 |  |  | 16,896 |
Food + Beverage | 229 |  |  | 606 |  |  | 881 |  |  | 1,808 |
Total Intersegment Sales | $ | 7,193 |  |  | $ | 8,809 |  |  | $ | 29,613 |  |  | $ | 28,022 |
Net Sales: |  |  |  |  |  |  |
Pharma | $ | 343,397 |  |  | $ | 313,225 |  |  | $ | 1,026,090 |  |  | $ | 952,400 |
Beauty + Home | 359,823 |  |  | 374,088 |  |  | 1,099,368 |  |  | 1,081,280 |
Food + Beverage | 133,640 |  |  | 138,129 |  |  | 400,877 |  |  | 379,548 |
Net Sales | $ | 836,860 |  |  | $ | 825,442 |  |  | $ | 2,526,335 |  |  | $ | 2,413,228 |
Adjusted EBITDA (1): |  |  |  |  |  |  |
Pharma | $ | 107,235 |  |  | $ | 100,738 |  |  | $ | 333,793 |  |  | $ | 315,201 |
Beauty + Home | 41,230 |  |  | 43,789 |  |  | 125,607 |  |  | 117,055 |
Food + Beverage | 18,816 |  |  | 22,379 |  |  | 55,756 |  |  | 61,995 |
Corporate & Other, unallocated | (13,537) |  |  | (12,745) |  |  | (45,170) |  |  | (40,311) |
Acquisition-related costs (2) | (231) |  |  | (1,793) |  |  | (231) |  |  | (4,227) |
Restructuring Initiatives (3) | (2,270) |  |  | (10,223) |  |  | (2,989) |  |  | (18,771) |
Net unrealized investment gain (loss) (4) | 277 |  |  | (9,021) |  |  | (2,297) |  |  | 6,177 |
Depreciation and amortization | (57,601) |  |  | (59,280) |  |  | (174,818) |  |  | (174,508) |
Interest Expense | (9,756) |  |  | (8,011) |  |  | (30,668) |  |  | (22,601) |
Interest Income | 752 |  |  | 401 |  |  | 2,029 |  |  | 1,406 |
Income before Income Taxes | $ | 84,915 |  |  | $ | 66,234 |  |  | $ | 261,012 |  |  | $ | 241,416 |
________________________________________________ (1)We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. (2)Acquisition-related costs include transaction costs related to acquisitions (see Note 17 – Acquisitions for further details). (3)Restructuring Initiatives includes expense items for the three and nine months ended September 30, 2022 and 2021 as follows (see Note 19 – Restructuring Initiatives for further details):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Restructuring Initiatives by Segment |  |  |  |  |  |  |
Pharma | $ | — |  |  | $ | 13 |  |  | $ | — |  |  | $ | 86 |
Beauty + Home | 2,344 |  |  | 5,442 |  |  | 3,022 |  |  | 7,995 |
Food + Beverage | (74) |  |  | 131 |  |  | (33) |  |  | 169 |
Corporate & Other | — |  |  | 4,637 |  |  | — |  |  | 10,521 |
Total Restructuring Initiatives | $ | 2,270 |  |  | $ | 10,223 |  |  | $ | 2,989 |  |  | $ | 18,771 |
(4)Net unrealized investment gain (loss) represents the change in fair value of our investment in PCT (see Note 18 – Investment in Equity Securities for further details).

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration